EDI Therapeutics LLC
Rochester, NY
- UEI
- P6VEXK48QFJ8
- CAGE
- Not on record
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 601 Elmwood Ave, Rochester, NY 14642, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of EDI-239382, a novel IRAK4 inhibitor to control inflammation driven metastasis, immune dysfunction and… | National Cancer Institute | $377,537 | |
| Chimectin as a novel wound biologic for xylazine-induced tissue injury - abstract the opioid epidemic has led to… | National Institute on Drug Abuse | $274,219 | |
| Fibronectin matrix mimetic, chimectin as a first-in-class therapeutic for chronic wound healing - abstract chronic… | National Institute of Diabetes and Digestive and Kidney Diseases | $388,193 |
Quick answers
What is EDI Therapeutics LLC's UEI?
EDI Therapeutics LLC's Unique Entity ID (UEI) in SAM.gov is P6VEXK48QFJ8.
Where is EDI Therapeutics LLC located?
EDI Therapeutics LLC's physical address in SAM.gov is 601 Elmwood Ave, Rochester, NY 14642, USA.
Is EDI Therapeutics LLC registered in SAM.gov?
Yes. EDI Therapeutics LLC's SAM.gov registration is active through January 1, 2027.
What is EDI Therapeutics LLC's most recent federal award?
EDI Therapeutics LLC's most recent federal grant award is Development of EDI-239382, a novel IRAK4 inhibitor to control inflammation driven metastasis, immune dysfunction and… (R43CA309899), from National Cancer Institute, on September 1, 2026.
On GovTribe
See EDI Therapeutics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors